{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:46:18Z","timestamp":1792712778687,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.semarthrit.2006.02.001","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T22:40:18Z","timestamp":1152225618000},"page":"159-167","source":"Crossref","is-referenced-by-count":186,"title":["Tumor Necrosis Factor Antagonists: Different Kinetics and\/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection"],"prefix":"10.1016","volume":"36","author":[{"given":"Daniel E.","family":"Furst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Beenhouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2006.02.001_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0162-3109(00)00184-3","article-title":"Methotrexate use in rheumatoid arthritis","volume":"47","author":"Alarcon","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib2","unstructured":"New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated with ENBREL Plus Methotrexate Had No Progression of Joint Damage. http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?year=2004&releaseID=631786. Accessed December 5, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib3","unstructured":"500,000 patients have now been treated with REMICADE\u00ae worldwide. News-Medical.Net (Pharmaceutical News), April 21, 2004. http:\/\/www.news-medical.net\/?id=729. Accessed November 29, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib4","author":"Schiff","year":"2005","journal-title":"Safety of adalimumab (Humira) in global clinical trials of patients with early vs long-standing rheumatoid arthritis (RA)"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib7","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00013","article-title":"Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis","volume":"62","author":"Culy","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib8","unstructured":"Product Approval Information: Licensing Action. Adalimumab\u2014for use in the treatment of rheumatoid arthritis: Clinical Review. Abbott Laboratories Biologic Licensing Application, 1-136. Approved December 31, 2003. Office of Therapeutics Research and Review; Division of Clinical Trial Design and Analysis; Immunology and Infectious Diseases Branch. Available at http:\/\/www.fda.gov\/cder\/biologics\/review\/adalabb123102r1.htm. Accessed December 1, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib9","author":"Reynolds","year":"2003","journal-title":"A comparison of the efficacy of etanercept and adalimumab in patients with rheumatoid arthritis: results of a meta-analysis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib10","author":"Singh","year":"2003","journal-title":"A meta-analysis of biological response modifiers in the treatment of rheumatoid arthritis for patients failing one or more disease modifying antirheumatic drugs"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases","volume":"46","author":"Gluck","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005176-200204000-00018","article-title":"Listeria meningitis after treatment with infliximab","volume":"34","author":"Kamath","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib16","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1572-0241.2001.03836.x","article-title":"Reactivation tuberculosis in a patient with anti-TNF-alpha treatment","volume":"96","author":"Nunez Martinez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib19","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab","volume":"29","author":"True","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0002-9343(02)01205-6","article-title":"Exacerbation of tuberculosis enteritis after treatment with infliximab","volume":"113","author":"Liberopoulos","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib22","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"6918","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib23","author":"Perez","year":"2005","journal-title":"Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib27","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib28","first-page":"145","article-title":"The tumour necrosis factor family of receptors\/ligands in the serum of patients with rheumatoid arthritis","volume":"9","author":"Robak","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/BF01957501","article-title":"Definition of a new score for severity of generalized Neisseria meningitis infection","volume":"154","author":"Nurnberger","year":"1995","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/cyto.2002.1010","article-title":"Peaks of endogenous G-CSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock","volume":"17","author":"Barth","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/rheumatology\/38.3.202","article-title":"Cytokine production by synovial T cells in rheumatoid arthritis","volume":"38","author":"Steiner","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0065-2776(08)60405-8","article-title":"Confrontation between intracellular bacteria and the immune system","volume":"71","author":"Schaible","year":"1999","journal-title":"Adv Immunol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/clinids\/23.1.146","article-title":"Granulomatous infections: etiology and classification","volume":"23","author":"Zumla","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1126\/science.285.5428.732","article-title":"Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors","volume":"285","author":"Brightbill","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib37","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1073\/pnas.87.9.3348","article-title":"Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot","volume":"87","author":"Wallis","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1128\/IAI.69.3.1755-1765.2001","article-title":"Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms","volume":"69","author":"Brill","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib39","first-page":"416","article-title":"CD1 proteins: targets of T cell recognition in innate and adaptive immunity","volume":"2","author":"Ulrichs","year":"2000","journal-title":"Rev Immunogenet"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/jcpa.2000.0427","article-title":"Lymphocyte subtypes in experimentally induced early-stage bovine tuberculous lesions","volume":"124","author":"Cassidy","year":"2001","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2174\/1566524023361880","article-title":"Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes","volume":"2","author":"Poccia","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2567.2003.01600.x","article-title":"Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cells","volume":"108","author":"Ferrero","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib43","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1126\/science.1068819","article-title":"Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections","volume":"295","author":"Shen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib45","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","article-title":"Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin","volume":"162","author":"Bean","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib46","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1128\/IAI.59.9.3213-3218.1991","article-title":"Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates","volume":"59","author":"Flesch","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1365-2567.2001.01161.x","article-title":"Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology","volume":"102","author":"Turner","year":"2001","journal-title":"Immunology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib49","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1164\/ajrccm.157.6.9705028","article-title":"Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide","volume":"157","author":"Aston","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib50","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1128\/IAI.70.8.4716-4720.2002","article-title":"CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes","volume":"70","author":"Larkin","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.282.5386.121","article-title":"An antimicrobial activity of cytolytic T cells mediated by granulysin","volume":"282","author":"Stenger","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib52","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1126\/science.291.5508.1544","article-title":"Induction of direct antimicrobial activity through mammalian toll-like receptors","volume":"291","author":"Thoma-Uszynski","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib53","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn\u2019s disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib56","author":"Ruderman","year":"2003","journal-title":"Granulomatous infections and tumor necrosis factor antagonist therapies"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib57","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/CMR.8.2.180","article-title":"Tuberculosis in the AIDS era","volume":"8","author":"Sepkowitz","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/clind\/16.4.513","article-title":"Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States","volume":"16","author":"Slutsker","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib61","article-title":"Etanercept (Enbrel\u00ae) Prescribing Information","year":"2002","journal-title":"Package Insert"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib62","unstructured":"Centocor. Infliximab (Remicade\u00ae) Prescribing Information. Available at http:\/\/www.remicade.com\/pdf\/HCP_PPI.pdf. Accessed December 1, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib63","article-title":"Humira\u2122(adalimumab)Prescribing Information","year":"2003","journal-title":"Package Insert"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abio.2001.5380","article-title":"Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore","volume":"299","author":"Santora","year":"2001","journal-title":"Anal Biochem"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib66","unstructured":"EMEA (European Agency for the Evaluation of Medicinal Products) 2002 Remicade Scientific Discussion. 2003. Available at http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPAR\/Remicade\/190199en6.pdf. Accessed December 1, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib68","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.156.4.1646","article-title":"In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis","volume":"156","author":"Lorenz","year":"1996","journal-title":"J Immunol"},{"issue":"suppl","key":"10.1016\/j.semarthrit.2006.02.001_bib69","first-page":"S90","article-title":"Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion","volume":"42","author":"Barone","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib70","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Van Den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib71","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib72","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.20764","article-title":"Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report","volume":"52","author":"Catrina","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.193.2.239","article-title":"Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection","volume":"193","author":"Roach","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib75","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","article-title":"Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection","volume":"335","author":"Jouanguy","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/art.10847","article-title":"Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab","volume":"48","author":"Zou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib78","author":"Wallis","year":"2005","journal-title":"Effect of TNF blockers on expression of mycobacterial immunity in vitro"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib79","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002-2003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib80","first-page":"433","article-title":"Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis","volume":"8","author":"Paimela","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF00918190","article-title":"Depressed T-cell reactivity to recall antigens in rheumatoid arthritis","volume":"10","author":"Verwilghen","year":"1990","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02715694","article-title":"Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy","volume":"3","author":"Helliwell","year":"1984","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2006.02.001_bib83","unstructured":"EMEA (European Agency for the Evaluation of Medicinal Products) 2002 Enbrel Scientific Discussion. 2004 Update. Available at http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPAR\/Enbrel\/014600en6.pdf. Accessed December 1, 2005."},{"key":"10.1016\/j.semarthrit.2006.02.001_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/351501a0","article-title":"Humanized antibodies for therapy","volume":"351","author":"Co","year":"1991","journal-title":"Nature"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017206000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017206000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T23:57:52Z","timestamp":1683503872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017206000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0049017206000229"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2006.02.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}